Cardium, InnerCool complete $5M commercial financing

TriMed Staff | | Health Imaging | Screening
Cardium Therapeutics and its subsidiary, InnerCool Therapies, have completed a $5 million commercial credit facility with Life Sciences Capital to support the launch of InnerCool’s new product lines for patient temperature modulation and other ongoing product development activities.

Christopher J. Reinhard, chairman and CEO of Cardium and InnerCool, said the “two next-generation systems are designed to advance InnerCool to the forefront of the emerging field of therapeutic hypothermia.”

Cardium and InnerCool, both headquartered in San Diego, are medical technology companies focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular and ischemic-related indications.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.